Efficacy of Repeat Review with Flexible Spectral Imaging Color Enhancement in Patients with no Findings by Capsule Endoscopy

Yuka Minami-Kobayashi, Atsuo Yamada, Hirotsugu Watabe, Hirobumi Suzuki, Yoshihiro Hirata, Yutaka Yamaji, Haruhiko Yoshida, Kazuhiko Koike

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Address for correspondence:
Dr. Yuka Minami-Kobayashi, Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo - 113-8655, Japan. E-mail: yukakobayashi-tky@umin.ac.jp

ABSTRACT

Background/Aim: The efficacy of flexible spectral imaging color enhancement (FICE) ch. 1 (F1) for the detection of ulcerative lesions and angioectasias in the small intestine with capsule endoscopy (CE) has been reported. In the present study, we evaluated whether F1 could detect incremental findings in patients with no findings in a standard review mode. Patients and Methods: In total, 52 patients (age: 60.1 ± 15.3 years; 30 males) with obscure gastrointestinal bleeding (OGIB) who underwent CE and in whom no lesion was detected in the small intestine in the standard mode (first review) were enrolled. Two experienced endoscopists independently reviewed CE videos again by F1 (second review). The following findings were defined to be significant: Ulcers, erosions, aphthas, angioectasias, tumors, and bleeding. Incremental findings at the second review were checked at F1 and in standard mode by the two reviewers (third review). Finally, the findings were confirmed by the agreement of the two reviewers at the third review. Results: F1 detected five significant lesions in three patients with overt OGIB: three erosions, one aphtha, and one angioectasia. For nonsignificant lesions, F1 detected 12 red mucosas and 16 red spots. Moreover, 29 patients with 71 findings were considered false positives. Conclusion: F1 detected incremental significant findings in a small percentage of patients with no findings in the standard review mode. In addition, F1 showed many false-positive findings. The incremental effect of a repeated review by F1 in patients with no findings in the first review is limited.

Key Words: Capsule endoscopy, flexible spectral imaging color enhancement, obscure gastrointestinal bleeding, repeat review, small intestinal lesion

Received: 17.04.2016, Accepted: 12.08.2016

How to cite this article: Minami-Kobayashi Y, Yamada A, Watabe H, Suzuki H, Hirata Y, Yamaji Y, et al. Efficacy of repeat review with flexible spectral imaging color enhancement in patients with no findings by capsule endoscopy. Saudi J Gastroenterol 2016;22:385-90.

Flexible spectral imaging color enhancement (FICE), an image-enhanced endoscopy (IEE) technique, has been used widely in gastroscopy and colonoscopy.[1,2] FICE depends on optical filters and the use of spectral estimation technology to reconstruct images at different wavelengths based on images from white-light endoscopy. It has been reported that it improves the visualization of both neoplastic and non-neoplastic lesions in gastroscopy and colonoscopy.[1-3] Capsule endoscopy (CE) has become an important examination of the small intestine.[6] The efficacy of CE for small intestinal diseases has been reported,[7-11] CE has demonstrated efficacy for patients with obscure gastrointestinal bleeding (OGIB). It can detect various kinds of disease states such as tumors, polyps, angioectasias, ulcers, and erosions.

Rapid 6.5 (Given Imaging Ltd., Yoqneam, Israel), a CE reading system, includes FICE.[12] Several studies have shown the effects of FICE in CE.[11-20] In a previous study, we found...
that FICE Ch. 1 (F1) detected a larger number of ulcerative lesions and angioectasias in the small intestine compared to a standard review.\[16\] However, little is known about the impact of FICE on CE in patients, with no findings in the standard mode CE. In the present study, we investigated whether F1 could detect incremental findings in patients with no findings in the standard review mode.

PATIENTS AND METHODS

Study design
This study was a retrospective analysis, conducted in accordance with the Declaration of Helsinki. All study participants provided written informed consent.

Subjects
Between March 2008 and November 2011, 52 patients (age: 60.1 ± 15.3 years; 30 males) with OGIB who underwent CE and in whom no lesion was detected in the small intestine in the standard mode (first review) were enrolled. OGIB was defined as recurrent or persistent overt/visible bleeding, iron deficiency anemia (IDA), or a positive fecal occult blood test (FOBT) with no bleeding source found during the initial endoscopic evaluation.\[21\] OGIB was classified as overt or occult OGIB. Overt OGIB was defined as clinically perceptible bleeding that recurred or persisted after a negative initial endoscopic evaluation by esophagogastroduodenoscopy (EGD) and colonoscopy. In comparison, occult OGIB was defined as IDA with or without a positive FOBT.\[22\]

Capsule endoscopy procedures
We used Pillcam SB or SB2 (Given Imaging Ltd., Yoqneam, Israel) in all study patients. Preparation for CE involved fasting for 12 h and administration of 40 mg simethicone immediately before CE. Eating was allowed after 5 h. During the examination, patients could move freely. CE was performed for approximately 8 h after ingesting, and sensor array and recording devices were then removed.

Two or more experienced endoscopists reviewed all CE videos independently in the standard mode (first review). CE images were reviewed using the Rapid 6.5 Access software (Given Imaging Ltd.). An independent review was performed to reach a consensus on CE findings [Figure 1].

Flexible spectral imaging color enhancement on capsule endoscopy
Three modes of FICE (FICE ch. 1 [F1], FICE ch. 2 [F2], and FICE ch. 3 [F3]) are implemented within Rapid 6.5. Switching between the standard mode and each FICE mode can be achieved with a button click at the workstation. The spectral specifications of the FICE channels were as follows: F1 (wavelengths: Red 595 nm, green 540 nm, blue 535 nm), F2 (wavelengths: Red 420 nm, green 520 nm, blue 530 nm), and F3 (wavelengths: Red 595 nm, green 570 nm, blue 415 nm). Each spectral wavelength was determined for the following reasons: F1, to reduce interference with bile; F2, to emphasize blood; and F3, to emphasize the difference between bile and blood. We used standard mode and F1 because we previously reported the efficacy of F1 for the detection of ulcerative lesions and angioectasias in the small intestine at CE.\[16\]

Data analysis
Two experienced endoscopists independently reviewed CE videos by F1 (second review) in patients with no findings in the standard review mode (first review). Incremental findings at the second review were checked again at F1 and standard mode by the two reviewers (third review). Finally, the findings were confirmed by agreement of the two reviewers at the third review. Findings judged not to be lesions in the third review were deemed to be false-positive lesions.

The following findings were defined as significant findings because these were at risk for bleeding: Ulcers, erosions, aphthas, angioectasias, tumors, and bleeding. Other findings, such as red mucosas and red spots, were defined as nonsignificant lesions.

We counted the number of incremental lesions detected at the second review and confirmed by the third review. The number of false-positive findings were also counted. Furthermore, we observed whether rebleeding occurred in patients. Follow-up care was performed at least once every 6 months. Rebleeding was defined as clinically perceptible bleeding after CE.

RESULTS

Baseline characteristics of the study patients
Baseline clinical characteristics of the study patients are summarized in Table 1. The mean age of the 52 patients (30 males, 22 females) was 60.1 ± 15.3 years.
Of them, 27 (52%) had overt OGIB and 25 (48%) had occult OGIB. Fifteen patients (29%) had past histories of abdominal surgery, including gastrectomy, cholecystectomy, appendectomy, and uterine myomectomy. During the recording period, the CE reached the cecum in 45 (87%) patients.

**Additional lesions detected by flexible spectral imaging color enhancement ch. 1**
F1 detected five significant lesions in 3 of the 52 patients; 3 erosions, 1 aphtha, and 1 angioectasia [Table 2; Figure 2a and b]. All three cases with significant lesions were patients with overt OGIB. Regarding nonsignificant lesions, F1 detected 12 red mucosas and 16 red spots.

**Misdiagnosed findings by flexible spectral imaging color enhancement ch. 1**
In total, 29 cases with 71 findings were considered to be false positives [Table 2]. The following were misdiagnosed findings; 6 erosions, 42 red mucosas, 22 red spots, and 1 case of bleeding. For the 6 findings misdiagnosed as erosions, the correct diagnoses were; 2 residues [Figure 3a], 1 lymphoid follicle, 1 bubble, 1 vessel, and 1 reflected light. For the 42 findings misdiagnosed as red mucosas, 32 were shadowed areas of normal mucosa, 4 were vessels, and 2 were bile. Approximately two-thirds of the 22 findings misdiagnosed as red spots were, in fact, residues, and others were bubbles and shadowed areas of normal mucosa [Figure 3b]. One finding misdiagnosed as bleeding was, in fact, bile [Figure 3c]. In many false-positive cases, residue or roughness of the mucosa was enhanced in red in F1.

**Follow-up of patients**
We followed the study patients for 46.7 ± 7.5 months. There was no case of rebleeding.

**DISCUSSION**
We assessed whether FICE ch. 1 could detect incremental small-intestinal findings in patients with no findings by capsule endoscopy.

---

**Table 1: Baseline characteristics of the study patients (n=52)**

| Characteristics                  | Value          |
|----------------------------------|----------------|
| Age (years)†                     | 60.1±15.3      |
| Male/Female                      | 30 (58%)/22 (42%) |
| Indications of CE                |                |
| Overt OGIB                       | 27 (52%)       |
| Occult OGIB                      | 25 (48%)       |
| Past history of abdominal surgery| 15 (29%)       |
| Percentage of capsule obtained cecum image | 87%       |
| Daily using drugs                |                |
| NSAIDs                           | 3 (6%)         |
| Antiplatelet agent               | 5 (10%)        |

CE: capsule endoscopy; OGIB: obscure gastrointestinal bleeding; NSAIDs, nonsteroidal anti-inflammatory drugs; †Mean±SD

**Table 2: Additional lesions and misdiagnosed findings detected by F1 in patients with no findings by capsule endoscopy**

| Additional lesions detected by F1 | Number of lesions | Misdiagnosed findings by F1 | Number of lesions (Correct diagnosis) |
|----------------------------------|-------------------|-----------------------------|---------------------------------------|
| Significant lesions              |                   |                             |                                       |
| Erosion                          | 3                 | Erosion                     | 6 (2 residues, 1 lymphoid follicle, 1 bubble, 1 vessel, 1 reflect light) |
| Aphtha                           | 1                 | Bleeding                    | 1 (bile)                              |
| Angioectasia                     | 1                 | Res mucosa                  | 42 (32 shadowed areas of normal mucosa, 4 vessels, 3 residues, 2 bile, 1 bubble) |
|                                 |                   | Red spot                    | 22 (16 residues, 3 bubbles, 3 shadowed areas of normal mucosa) |
| Nonsignificant lesions           |                   |                             |                                       |
| Red mucosa                       | 12                |                             |                                       |
| Red spot                         | 16                |                             |                                       |

F1, Flexible spectral imaging color enhancement ch. 1

---

**Figure 2:** Capsule endoscopy images of small-intestinal significant lesions detected at the second review (left; standard mode, right; F1). (a) erosion (b) angioectasia
the standard review mode of CE. F1 did detect additional significant lesions in 3 of 52 patients with no findings in the standard review mode. However, there was no case of rebleeding during the follow-up period.

Several previous studies have reported the efficacy of FICE in CE for detecting angioectasia and ulcerative lesions. We previously reported the efficacy of F1 for detecting ulcerative lesions and angioectasias in the small intestine. Imagawa et al. also reported that F1 and F2 had higher detectability for angioectasias. Konishi et al. showed that F1 and F2 were more useful for the detection of erosions than the standard mode. In the present study, the incremental small-intestinal findings by F1 were 3 erosions, 1 aphtha, and 1 angioectasia, which is consistent with previous studies.

However, we showed that F1 also picked up many false-positive findings. The following were misdiagnosed findings: 6 erosions, 42 red mucosas, 22 red spots, and 1 case of bleeding. The reasons for the misdiagnoses are thought to be similar to those for the incremental findings. In many false-positive cases, residues and roughness of the mucosa were enhanced in red with F1. Furthermore, while FICE enhances the color contrast to avoid interference by bile, this reduces the quality of the image’s resolution. Such diminished resolution interferes with the correct diagnosis.

All 3 cases with significant lesions were patients with overt OGIB, although it made no sense to analyze the data statistically because of the small number of cases. Several studies have reported that the diagnostic yield of CE for small intestinal lesions in patients with overt OGIB is significantly higher than that in patients with occult OGIB. However, other studies have shown that there is no difference in the diagnostic yield of CE between patients with previous overt and occult OGIB. Although the difference in the diagnostic yield of CE between patients with overt and occult OGIB is controversial, a higher prevalence of small intestinal lesions in overt OGIB may be associated with this result.

It is unclear whether we should review videos at F1 practically in patients with no finding in the standard mode. Although incremental findings were detected at the second review, there was no case of rebleeding during the follow-up period (46.7 ± 7.5 months). Hence, it would seem that a detailed examination or hemostatic therapy was not required in these cases. Therefore, a second review by F1 may not be necessarily required in terms of clinical practice according to the present study. However, we did not analyze the data statistically because of the small number of cases. Clinically, management change such as close follow-up or a detailed examination could decrease rebleeding rate if further experience is accumulated. Furthermore, it takes twice as long to review CE videos in both F1 and standard mode. Although reviewing CE in both F1 and standard mode may be unrealistic until a computer-aided diagnosis system is established, further experience is needed to assess the feasibility and efficacy of reviewing in both modes. At present, the efficacy of FICE in CE is such that FICE improves the detectability of ulcerative lesions or angioectasias in patients with small bowel lesions, as reported previously. Additional review by FICE should be performed only in cases where significant lesions were detected in the standard review for enhanced visualization, which may improve lesion diagnosis.

Potential limitations of our study should be noted. First, the study was retrospective and relatively few patients
were enrolled. Second, a detailed examination, such as a balloon enteroscopy, was not performed in any patient with additional significant lesions by F1 because this was a retrospective study.

CONCLUSION

Among patients with OGIB, F1 detected incremental small intestinal lesions in a small percentage of patients with no findings in the standard review mode. However, it also detected many false-positive findings. The incremental effect of repeated review by F1 in patients with no findings in the first review is limited.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Pohl J, May A, Rabenstein T, Pech O, Ell C. Computed virtual chromoendoscopy: A new tool for enhancing tissue surface structures. Endoscopy 2007;39:803-8.
2. Gono K, Obi T, Yamaguchi M, Ohyama N, Machida H, Sano Y, et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt 2004;9:568-77.
3. Mouri R, Yoshida S, Tanaka S, Oka S, Yoshihara M, Chayama K. Evaluation and validation of computed virtual chromoendoscopy in early gastric cancer. Gastrointest Endosc 2009;69:1052-8.
4. Pohl J, Nguyen-Tat M, Pech O, May A, Rabenstein T, Ell C. Computed virtual chromoendoscopy for classification of small colorectal lesions: A prospective comparative study. Am J Gastroenterol 2008;103:562-9.
5. Pohl J, May A, Rabenstein T, Pech O, Nguyen-Tat M, Fissler-Eckhoff A, et al. Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett’s esophagus. Endoscopy 2007;39:594-8.
6. Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000;405:417.
7. Pennazio M, Santucci R, Rondonotti E, Abiarti C, Becarri G, Rossini FP, et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: Report of 100 consecutive cases. Gastroenterology 2004;126:643-53.
8. Apostolopoulos P, Liatsos C, Gralnek IM, Kalantzis C, Giannakouloupoulou E, Alexandakis G, et al. Evaluation of capsule endoscopy in active, mild-to-moderate, overt, obscure GI bleeding. Gastrointest Endosc 2007;66:1174-81.
9. Urbain D, De Looze D, Demedts I, Louis E, Dewil O, Macken E, et al. Video capsule endoscopy in small-bowel malignancy: A multicenter Belgian study. Endoscopy 2006;38:408-11.
10. Costamagna G, Shah SK, Riccioni ME, Foschia F, Mutignani M, Perri V, et al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. Gastroenterology 2002;123:999-1005.
11. Fukumoto A, Tanaka S, Shishido T, Takemura Y, Oka S, Chayama K. Comparison of detectability of small-bowel lesions between capsule endoscopy and double-balloon endoscopy for patients with suspected small-bowel disease. Gastrointest Endosc 2009;69:857-65.
12. Pohl J, Aschmoneit I, Schuhmann S, Ell C. Computed image modification for enhancement of small-bowel surface structures at video capsule endoscopy. Endoscopy 2010;42:490-2.
13. Imagawa H, Oka S, Tanaka S, Noda I, Higashiyama M, Sanomura Y, et al. Improved visibility of lesions of the small intestine via capsule endoscopy with computed virtual chromoendoscopy. Gastrointest Endosc 2011;73:299-306.
14. Imagawa H, Oka S, Tanaka S, Noda I, Higashiyama M, Sanomura Y, et al. Improved detectability of small-bowel lesions via capsule endoscopy with computed virtual chromoendoscopy: A pilot study. Scand J Gastroenterol 2011;46:1133-7.
15. Gupta T, Ibrahim M, Deviere J, Van Gossum A. Evaluation of Fujinon intelligent chromo endoscopy-assisted capsule endoscopy in patients with obscure gastroenterology bleeding. World J Gastroenterol 2011;17:4590-5.
16. Kobayashi Y, Watabe H, Yamada A, Hirata Y, Yamaji Y, Yoshida H, et al. Efficacy of flexible spectral imaging color enhancement on the detection of small intestinal diseases by capsule endoscopy. J Dig Dis 2012;13:614-20.
17. Konishi M, Shibuya T, Mori H, Kurashita E, Takeda T, Nomura O, et al. Usefulness of flexible spectral imaging color enhancement for the detection and diagnosis of small intestinal lesions found by capsule endoscopy. Scand J Gastroenterol 2014;49:501-5.
18. Maeda M, Hiraishi H. Efficacy of video capsule endoscopy with flexible spectral imaging color enhancement at setting 3 for differential diagnosis of red spots in the small bowel. Dig Endosc 2014;26:228-31.
19. Boal Carvalho P, Magalhães J, Dias de Castro F, Goncalves TC, Rosa B, Moreira MJ, et al. Virtual chromoendoscopy improves the diagnostic yield of small bowel capsule endoscopy in obscure gastrointestinal bleeding. Dig Liver Dis 2016;48:172-5.
20. Sato Y, Sagawa T, Hirakawa, Ohnuma H, Osuga T, Okagawa Y, et al. Clinical utility of capsule endoscopy with flexible spectral imaging color enhancement for diagnosis of small bowel lesions. Endosc Int Open 2014;2:680-7.
21. Zuckerman GR, Prakash C, Askin MP, Lewis BS. AGA technical review on the evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000;118:201-21.
22. Leighton JA, Goldstein J, Hirota W, Jacobson BC, Johanson JF, Mallery JS, et al. Obscure gastrointestinal bleeding. Gastroenterology 2003;58:650-5.
23. Redondo-Cerezo E, Pérez-Vigara G, Pérez-Sola A, Gómez-Ruiz CJ, Chicano MV, Sánchez-Manjavacas N, et al. Diagnostic yield and impact of capsule endoscopy on management of patients with gastrointestinal bleeding of obscure origin. Dig Dis Sci 2007;52:1376-81.
24. Carey EJ, Leighton JA, Heigh RI, Shiff AD, Sharma VK, Post JK, et al. A single-center experience of 260 consecutive patients undergoing capsule endoscopy for obscure gastrointestinal bleeding. Am J Gastroenterol 2007;102:89-95.
25. Apostolopoulos P, Liatsos C, Gralnek IM, Giannakouloupoulou E, Alexandakis G, Kalantzis C, et al. The role of wireless capsule endoscopy in investigating unexplained iron deficiency anemia after negative endoscopic evaluation of the upper and lower gastrointestinal tract. Endoscopy 2006;38:1127-32.
26. Goenka MK, Majumder S, Kumar S, Sethy PK, Goenka U. Single center experience of capsule endoscopy in patients with obscure gastrointestinal bleeding. World J Gastroenterol 2011;17:774-8.

FICE for negative capsule endoscopy
27. Sakai E, Endo H, Taniguchi I, Hata Y, Ezuka A, Nagase H, et al. Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding. Dig Endosc 2013;25:412-20.

28. Watari I, Oka S, Tanaka S, Nakano M, Aoyama T, Yoshida S, et al. Is Occult Obscure Gastrointestinal Bleeding a Definite Indication for Capsule Endoscopy? A Retrospective Analysis of Diagnostic Yield in Patients with Occult versus Overt Bleeding. Gastroenterol Res Pract 2013:2013:915463.

29. Sheibani S, Levesque BG, Friedland S, Roost J, Gerson LB. Long-term impact of capsule endoscopy in patients referred for iron-deficiency anemia. Dig Dis Sci 2010;55:703-8.